METHOD FOR PREVENTION OF TUBERCULOUS PROCESS REACTIVATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE OF FIFTH STAGE UNDERGOING PROGRAM HAEMODIALYSIS Russian patent published in 2025 - IPC A61K31/195 A61K31/496 A61K31/4409 A61P31/06 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to phthisiology, and can be used for prevention of tuberculosis process reactivation in patients with chronic kidney disease undergoing programmed haemodialysis. Previously, the history of tuberculosis is studied and the patients are divided into groups of patients, including the first group of patients with the presence of contraindications to the use of isoniazid, in the second group of patients with the presence of contraindications to the use of rifampicin, in the third group of patients with the presence of contraindications to the use of isoniazid and rifampicin. For the first group of patients, the duration of chemoprophylaxis (CP) is 2 months of taking a two-component combination: rifampicin in dose of 50% of the therapeutic dose calculated according to the patient's weight, and ethambutol in dose of 5–7.5 mg/kg/day. For the second group of patients, CP is 2 months of taking a two-component combination: isoniazid in dose of 200–300 mg/day and ethambutol in dose of 5–7.5 mg/kg/day. For the third group of patients, CP is 2 months of a two-component combination: ethambutol in dose of 5–7.5 mg/kg/day and moxifloxacin 400 mg/day. Above anti-tuberculosis preparations are taken daily.

EFFECT: method enables avoiding tuberculous process reactivation with underlying programmed haemodialysis by using said chemoprophylaxis regimens.

2 cl, 6 dwg, 3 ex